Product Discontinuation Notice

Dear Customer,

after careful consideration, QIAGEN has decided to discontinue the production of the aLF Reader with May 30, 2021 as final date of order placement and June 30, 2021 as final date of delivery. We will continue to provide lifecycle and service support until June 30, 2026.

While we regret any inconvenience this announcement may cause, we are pleased to supply you with alternate reader solutions for rapid testing from our subsidiary company DIALUNOX GmbH. Feel free to contact us for further questions.

Gamechanger In The Field of Cancer Diagnosis

QIAGEN Lake Constance is proud to announce a new test named PT Monitor® of our aLF Partner Abviris Deutschland GmbH.

PT Monitor® is a competitive immunoassay in rapid test format for the quantitative determination of DRH1 antibody equivalents in serum using the antibody clone DRH1.

The antibody concentration is associated with HPV16 induced precancerous lesions and tumors which are usually located in the oral and pharyngeal and anogenital area.

PT Monitor® is a single use test which is dedicated to professional users.

In combination with our aLF platform, this could be a gamechanger in the field of early HPV cancer diagnosis. Click here to learn more: